Quadria Capital is reportedly in talks to acquire a majority stake in Samarth Lifesciences, with the deal potentially valuing the company at about Rs 4,500 crore. The pharma firm is seeking fresh investment to support growth plans after earlier negotiations with alternative investors broke down due to mismatches in price expectations.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
